REG - Fusion Antibodies - Director/PDMR Shareholding

Fusion AntibodiesAnnouncement

04/12/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231204:nRSD5920Va&default-theme=true

RNS Number : 5920V  Fusion Antibodies PLC  04 December 2023

4 December 2023

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Director/PDMR Shareholdings

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, has been notified of the following purchases of ordinary shares
of 4 pence each in the Company ("Ordinary Shares") by certain Directors of
Fusion.

 

Simon Douglas, Non-Executive Chair, has purchased 100,565 Ordinary Shares at
an average price of 4.96 pence per share. Following this purchase, Simon
Douglas directly holds 356,365 Ordinary Shares, representing approximately
0.60 per cent. of the Company's issued share capital.

 

Adrian Kinkaid, Chief Executive Officer, has purchased 101,847 Ordinary Shares
at an average price of 4.90 pence per share. Following this purchase, Adrian
Kinkaid holds 245,847 Ordinary Shares, representing approximately 0.41 per
cent. of the Company's issued share capital.

 

Further details of the respective purchases are outlined in the tables below.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Simon Douglas
 2    Reason for the notification
 a)   Position/status                                              Non-Executive Chair
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Fusion Antibodies plc
 b)   LEI                                                          213800KBAYRC9VOQ9V39
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  ordinary shares of 4p each in Fusion Antibodies plc

      Identification code

                                                                   Identification code (ISIN) for Fusion Antibodies plc ordinary shares:
                                                                   GB00BDQZGK16
 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)                                        Price(s)   Volume(s)

                                                            4.96p       100,565

 d)   Aggregated information

      - Aggregated volume                                          -      See above

      - Price                                                      -      See above
 e)   Date of the transaction                                      4 December 2023
 f)   Place of the transaction                                     XLON, London Stock Exchange

d)

Aggregated information

- Aggregated volume

- Price

 

-      See above

-      See above

e)

Date of the transaction

4 December 2023

f)

Place of the transaction

XLON, London Stock Exchange

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Adrian Kinkaid
 2    Reason for the notification
 a)   Position/status                                              Chief Executive Officer
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Fusion Antibodies plc
 b)   LEI                                                          213800KBAYRC9VOQ9V39
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  ordinary shares of 4p each in Fusion Antibodies plc

      Identification code

                                                                   Identification code (ISIN) for Fusion Antibodies plc ordinary shares:
                                                                   GB00BDQZGK16
 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)                                        Price(s)   Volume(s)

                                                            4.90p       101,847

 d)   Aggregated information

      - Aggregated volume                                          -      See above

      - Price                                                      -      See above
 e)   Date of the transaction                                      4 December 2023
 f)   Place of the transaction                                     XLON, London Stock Exchange

d)

Aggregated information

- Aggregated volume

- Price

 

-      See above

-      See above

e)

Date of the transaction

4 December 2023

f)

Place of the transaction

XLON, London Stock Exchange

 

Enquiries:

 

 Fusion Antibodies plc                                www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer              Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                              Tel: +44 (0)20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke (Sales and Corporate Broking)

 Walbrook PR               Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                          Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the discovery and development of
antibodies for both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody design,
generation, development, production, characterisation and optimisation. These
services include antigen expression, antibody production, purification and
sequencing, antibody humanisation using Fusion's proprietary
CDRx (TM) platform and the production of antibody generating stable cell
lines to provide material for use in clinical trials. Since 2012, the Company
has successfully sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international, blue-chip
client base, which has included eight of the top 10 global pharmaceutical
companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

The global monoclonal antibody therapeutics market was valued at $186 billion
in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR
of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal
antibody therapies are approved and marketed globally as of June 2022 with the
top four antibody drugs each having sales of more than $3 bn in 2021.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFSDFELEDSEEE